All In Biotech

Free tool

FAERS Monitor: Opcon-A

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020065 or its brand name (Opcon-A, Naphazoline Hydrochloride, Pheniramine Maleate). Reports on generic versions are filed under their own applications.

Reports

1,660

Serious

86

5% of reports

Hospitalization

25

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • mydriasis446
  • eye irritation425
  • vision blurred214
  • drug ineffective206
  • eye pain158
  • ocular hyperaemia149
  • instillation site pain104
  • condition aggravated74
  • eye pruritus66
  • lacrimation increased60
  • eye swelling48
  • visual impairment47
  • product quality issue41
  • headache39
  • burning sensation38

Reports by year received

View as table
YearReports
20041
20052
20062
20071
2008114
2009137
2010126
2011148
2012126
2013105
201488
201570
2016128
2017132
201825
201974
202044
202118
202250
202375
202449
202572
202673

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,499 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
instillation site painSignal104555.1458.954,589
mydriasisSignal446456.2420.6195,230
eye irritationSignal42594.286.838,933
ocular hyperaemiaSignal14939.934.25,607
eye painSignal15835.630.75,275
lacrimation increasedSignal6025.219.71,370
eye pruritusSignal6624.919.71,492
vision blurredSignal21419.817.43,815
eye swellingSignal4816.412.4678
burning sensationSignal386.95.0185
visual impairmentSignal474.83.6139
product quality issueSignal413.82.883
condition aggravatedSignal743.12.5104
drug ineffective2062.01.7106
headache390.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.